DE69232064T2 - Peptide als Amylin-Agonisten und ihre Verwendung - Google Patents

Peptide als Amylin-Agonisten und ihre Verwendung

Info

Publication number
DE69232064T2
DE69232064T2 DE69232064T DE69232064T DE69232064T2 DE 69232064 T2 DE69232064 T2 DE 69232064T2 DE 69232064 T DE69232064 T DE 69232064T DE 69232064 T DE69232064 T DE 69232064T DE 69232064 T2 DE69232064 T2 DE 69232064T2
Authority
DE
Germany
Prior art keywords
pro
ser
thr
asn
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232064T
Other languages
English (en)
Other versions
DE69232064D1 (de
Inventor
S Gaeta
Howard Jones
Elisabeth Albrecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Application granted granted Critical
Publication of DE69232064D1 publication Critical patent/DE69232064D1/de
Publication of DE69232064T2 publication Critical patent/DE69232064T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69232064T 1991-11-19 1992-11-19 Peptide als Amylin-Agonisten und ihre Verwendung Expired - Lifetime DE69232064T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79426691A 1991-11-19 1991-11-19
PCT/US1992/009842 WO1993010146A1 (en) 1991-11-19 1992-11-19 Amylin agonist peptides and uses therefor

Publications (2)

Publication Number Publication Date
DE69232064D1 DE69232064D1 (de) 2001-10-25
DE69232064T2 true DE69232064T2 (de) 2002-03-28

Family

ID=25162163

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232064T Expired - Lifetime DE69232064T2 (de) 1991-11-19 1992-11-19 Peptide als Amylin-Agonisten und ihre Verwendung

Country Status (17)

Country Link
EP (2) EP1162207A1 (de)
JP (4) JP2902115B2 (de)
AT (1) ATE205854T1 (de)
AU (1) AU714439B2 (de)
CA (1) CA2100745C (de)
CZ (1) CZ288029B6 (de)
DE (1) DE69232064T2 (de)
DK (1) DK0567626T3 (de)
ES (1) ES2161697T3 (de)
FI (1) FI118601B (de)
GR (1) GR3036794T3 (de)
HK (1) HK1041891A1 (de)
MD (1) MD960317A (de)
NO (2) NO324405B1 (de)
RU (1) RU2130463C1 (de)
SK (1) SK88793A3 (de)
WO (1) WO1993010146A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5625032A (en) * 1993-07-21 1997-04-29 Amylin Pharmaceuticals, Inc. Selective amylin antagonist peptides and uses therefor
KR100429966B1 (ko) * 1993-09-07 2004-05-04 아밀린 파마슈티칼스, 인크. 위장 운동성 조절을 위한 제약 조성물
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
AU760609B2 (en) * 1998-01-09 2003-05-15 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
GB0128583D0 (en) 2001-11-28 2002-01-23 Rsr Ltd Detection of autoantibodies indicative of diabetes
WO2004037168A2 (en) 2002-10-18 2004-05-06 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
CA2516726A1 (en) * 2003-03-18 2004-09-30 Applied Research Systems Ars Holding N.V. Amylin aggregation inhibitors and use thereof
CA2584906A1 (en) * 2004-10-26 2006-05-04 Lonza Ag S-alkyl-sulphenyl protection groups in solid-phase synthesis
US20090156474A1 (en) 2004-11-01 2009-06-18 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
ATE439140T1 (de) 2005-03-31 2009-08-15 Amylin Pharmaceuticals Inc Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
EA200900392A1 (ru) 2006-09-07 2010-06-30 Никомед Гмбх Комбинированное лечение сахарного диабета
EP2120985B1 (de) 2007-02-05 2012-06-27 Amylin Pharmaceuticals, Inc. FN-38 Peptide zur Verwendung bei der Behandlung Psychotischer- und Angsterkrankungen
JP2009149684A (ja) * 2009-03-11 2009-07-09 Amylin Pharmaceut Inc アミリン作動薬ペプチド用製剤
BRPI1009392A2 (pt) 2009-03-12 2016-03-08 Nordic Bioscience As "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
JP6657101B2 (ja) 2013-11-05 2020-03-04 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ 糖尿病及びそれから生じる疾患合併症の治療のための化合物
US10072060B2 (en) 2014-05-02 2018-09-11 The Research Foundation For The State University Of New York Islet amyloid polypeptides with improved solubility
PE20180497A1 (es) 2015-03-18 2018-03-09 Zealand Pharma As Analogos de amilina
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
US11028137B2 (en) 2017-02-01 2021-06-08 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same
KR102130354B1 (ko) * 2019-08-14 2020-07-06 엘아이지넥스원 주식회사 코어 제거용 이형장치
WO2023232781A1 (en) 2022-05-30 2023-12-07 Zealand Pharma A/S Liquid formulations of amylin analogues
WO2024061919A1 (en) 2022-09-19 2024-03-28 Zealand Pharma A/S Combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
DE68924372T2 (de) * 1988-01-11 1996-05-09 Amylin Pharmaceuticals Inc Behandlung von diabetes mellitus typ 2.
IE71195B1 (en) * 1989-07-10 1997-02-12 Amylin Corp Use of an amylin antagonist for the manufacture of a medicament for the treatment of obesity and essential hypertension and related disorders
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
WO1992015317A1 (en) * 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Synthetic preparation of amylin and amylin analogues

Also Published As

Publication number Publication date
JP2003238594A (ja) 2003-08-27
FI118601B (fi) 2008-01-15
AU673147B2 (en) 1996-10-31
JP4018116B2 (ja) 2007-12-05
AU714439B2 (en) 2000-01-06
ES2161697T3 (es) 2001-12-16
EP1162207A1 (de) 2001-12-12
GR3036794T3 (en) 2002-01-31
EP0567626A1 (de) 1993-11-03
NO324405B1 (no) 2007-10-08
CZ288029B6 (cs) 2001-04-11
EP0567626B1 (de) 2001-09-19
CA2100745C (en) 2007-07-31
FI933252A0 (fi) 1993-07-16
NO20073265L (no) 1993-09-17
JP2902115B2 (ja) 1999-06-07
NO932603D0 (no) 1993-07-19
DE69232064D1 (de) 2001-10-25
DK0567626T3 (da) 2001-12-17
SK88793A3 (en) 1994-12-07
ATE205854T1 (de) 2001-10-15
JPH11152299A (ja) 1999-06-08
AU3075392A (en) 1993-06-15
AU1245697A (en) 1997-03-27
CA2100745A1 (en) 1993-05-20
RU2130463C1 (ru) 1999-05-20
JP2006213716A (ja) 2006-08-17
NO932603L (no) 1993-09-17
HK1041891A1 (zh) 2002-07-26
FI933252A (fi) 1993-08-23
CZ168993A3 (en) 1994-04-13
JPH06504794A (ja) 1994-06-02
WO1993010146A1 (en) 1993-05-27
MD960317A (ro) 1998-05-31

Similar Documents

Publication Publication Date Title
ATE205854T1 (de) Peptide als amylin-agonisten und ihre verwendung
DE10075019I1 (de) Neue Proteine mit TNF-Hemmender wirkung und ihre Herstellung.
DE3750197D1 (de) Antagonisten des Fibroblasten-Wachstumsfaktors.
IL89541A0 (en) Urethane-protected amino acid-n-carboxyanhydrides and their use in the synthesis of polypeptides
WO1995030750A8 (fr) Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
ATE81779T1 (de) Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren.
DE69129865D1 (de) Osteogene peptide
ES2054365T3 (es) Inhibicion de la via de la regla del n final en celulas vivas.
DK0863155T3 (da) Suppression af T-celle-proliferation under anvendelse af peptidfragmenter af myelin basisk protein
ES489522A0 (es) Un procedimiento para la preparacion de un polipeptido
GB8821785D0 (en) Peptide compounds
Nitta et al. Primary structure of a ribonuclease from bullfrog (Rana catesbeiana) liver
EP0292257A3 (de) Peptide mit ANF-Wirksamkeit
DE3751398T2 (de) Substrat-Peptide.
ES2044928T3 (es) Enzima alfa-amidante en terminal c y procedimiento para la produccion y el uso del mismo.
CA2083286A1 (en) Recombinant fibrinogenases, preparation and use thereof
EP0687685A4 (de) Physiologisch-aktive peptide
DK200200302A (da) Rekombinante polypeptider omfattende aminosyresekvensen af moden vævsfaktorinhibitor (TFI), polypeptidfragmenter deraf, ekspressionsvektorer der koder for disse, værtsceller transformeret dermed, og fremgangsmåde til fremstilling af et ........
ES2051152B1 (es) Procedimiento de sistesis de peptidos con capacidad de detectar anticuerpos anti-virus de la hepatitis c (vhc) en suero de individuos afectados.
ES2069476A1 (es) Procedimiento de sintesis de peptidos con capacidad de detectar anticuerpos ant-virus de la hepatitis c (vhc) en suero de individuos afectados.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition